Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
Tyra Biosciences, Inc. director Dable Habib J filed an initial Form 3 reporting his ownership position in the company. The filing states that no securities are beneficially owned, meaning he reports holding zero Tyra Biosciences shares at this time.
Tyra Biosciences, Inc. is asking stockholders to vote at a fully virtual 2026 Annual Meeting on May 28, 2026. Holders of Common Stock at the close of business on April 2, 2026, when 59,485,237 shares were outstanding, are entitled to vote.
Stockholders will vote on electing three Class II directors—Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More—for terms expiring at the 2029 annual meeting, and on ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. The Board recommends voting in favor of all nominees and the auditor ratification.
Tyra Biosciences, Inc. expanded its board of directors from nine to ten members and appointed Habib J. Dable as a Class II director, with his initial term ending at the company’s 2026 annual meeting of stockholders. The board determined he qualifies as an independent director under Nasdaq rules.
In connection with his appointment, Dable received options to purchase 44,400 shares of Tyra’s common stock at the fair market value on the grant date, vesting in equal monthly installments over 36 months. He will also receive cash compensation under the company’s Non-Employee Director Compensation Program and has entered into Tyra’s standard indemnification agreement.
TYRA submitted a Form 144 notifying the proposed sale of 8,000 shares of Common stock. The filing lists shares outstanding of 53,372,098 as of 04/13/2026 and shows two prior sales by Daniel Bensen of 8,000 shares on 02/12/2026 and 8,000 shares on 03/12/2026.
FMR LLC reported beneficial ownership of 7,747,647.96 shares of Tyra Biosciences common stock, representing 14.4% of the class as of 03/31/2026. The filing shows FMR's sole voting power of 7,741,957 shares and sole dispositive power of 7,747,647.96 shares. The filing identifies Fidelity OTC Portfolio holding 2,694,729 shares (5.0%) as of the same date.
Tyra Biosciences, Inc. filed an initial insider report for Yuliya Rueb, Vice President, Finance (PAO), outlining her existing stock option holdings. The filing lists several options to buy common stock with exercise prices ranging from $6.50 to $21.57 per share and expirations between 2032 and 2035.
Each grant vests over time. One option began vesting on October 18, 2023 with 25% vested then and the remainder vesting monthly. Other grants vest in 48 monthly installments following commencement dates in July 2024, August 2024, and August 2025, conditioned on her continued service.
Tyra Biosciences, Inc. named Julia Rueb, its Vice President of Finance, as the company’s principal accounting officer, effective April 1, 2026. She succeeds Chief Financial Officer Alan Fuhrman in this specific role, while he continues to serve as the company’s principal financial officer.
Rueb, age 40, has been Vice President, Finance since January 2024 and previously held senior accounting and controller roles at the company. Her background includes technical accounting and consulting positions at SOAProjects, van den Boom & Associates, and audit experience at Ernst & Young, primarily serving public life sciences companies.
Tyra Biosciences director Gilla Kaplan reported option exercises and related share dispositions. Kaplan exercised stock options to acquire a total of 67,467 shares of common stock at an exercise price of $2.25 per share on March 25–26, 2026.
On March 25, 2026, Kaplan acquired 14,295 shares via option exercise and sold 14,295 shares of common stock in open-market transactions at a weighted average price of $36.9714 per share, with individual sale prices ranging from $36.95 to $37.11. On March 26, 2026, Kaplan exercised options for 53,172 shares and disposed of 53,172 shares back to the issuer at $37.7483 per share.
Following these transactions, Kaplan directly owned 28,231 shares of Tyra Biosciences common stock. The exercised options were reported as fully vested, and there are no remaining derivative positions shown in this filing.
TYRA proposed sale of 53,172 common shares via stock option exercise. The filing lists 53,172 shares to be sold on 03/26/2026 through a stock option exercise for cash to the issuer. The filing also shows 14,295 shares sold in the prior three months on 03/25/2026.